Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Phase: Phase 2
Diagnosis: Breast: Metastatic
NCT ID: NCT01307891
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-241
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable. One reason is due to the inability to develop specific therapies for specific cancer subsets. The use of modern genomic techniques has significantly enhanced our recent understanding of breast cancer biology. Five distinct breast cancer subsets have been recognized, one of which is basal-like breast cancer. Basal-like breast cancer is typically estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER-2-Neu) negative. This is referred to as triple negative breast cancer or TBNC. TBNC represents a significant proportion of breast cancer patients (10-20%) and has a poor prognosis with no targeted approach to therapy as of yet. Tigatuzumab is a humanized monoclonal antibody targeting a death receptor on the breast cancer cells. Previous studies have shown that combining antibodies with selected chemotherapy agents have induced tumor cell death. The hypothesis of this study is to use tigatuzumab and combine it with Abraxane to serve as a targeting agent in metastatic TBNC patients.
Dana-Farber Cancer Institute
Nancy Lin, MD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478
- Patients must have pathologically documented Stage IV breast cancer. If blocks
(paraffin-embedded tissue) from original diagnosis are available, they will be
obtained to confirm the diagnosis and for correlative studies. Fifteen slides can be
obtained from the block if the block is not available to be sent or released.
- Tumor must be HER-2-neu negative (defined as 0 or 1+ staining by immunohistochemistry
or gene amplification ratio less than or equal to 2.0, by fluorescent in situ
hybridization - FISH), estrogen and progesterone receptors negative (<10%).
- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded)
- Biopsy of a metastatic lesion is not required for protocol entry but all patients
with reasonably accessible lesions (chest wall, breast, skin, subcutaneous,
superficial lymph nodes, bones and liver metastases) must agree to biopsy.
1. Biopsies may be done with local anesthesia or intravenous conscious sedation,
according to standard institutional guidelines.
2. If a biopsy requires general anesthesia, then it is only allowed if acquisition
of tissue is necessary for clinical reasons and excess tissue that would
otherwise have been discarded is then used for research purposes. If a biopsy
requires general anesthesia, then a biopsy of that site for research purposes
only, without a coexisting clinical indication is not allowed on this protocol.
3. Patients with reasonably accessible lesions as described above, who will not
agree with the biopsy, will not be enrolled in the trial.
4. Patients with NO reasonably accessible lesions as described above can be
enrolled in the trial.
- There is no restriction as to the number of prior regimens for metastatic disease as
long as patients have adequate performance status. Patients with no prior
chemotherapy for metastatic disease and patients who have received prior therapy with
taxanes for metastatic disease (taxol or taxotere) are eligible. Stratification will
be used for randomization of these two categories (no prior chemotherapy for
metastatic disease or prior taxane therapy for metastatic disease).
- Chemotherapy treatment prior to enrollment must be discontinued for at least 3 weeks
prior to study entry.
- Patients must have completed radiation therapy at least 7 days prior to beginning
- Patients must have recovered from all reversible toxicities related to prior therapy
before beginning protocol treatment, and may not have any pre- existing
treatment-related toxicities in excess of grade 1. Patients must have < grade 2
pre-existing peripheral neuropathy.
- Patients may receive bisphosphonates; however, if used, bone lesions may not be used
for progression or response.
- At least 18 years of age (19 in Alabama).
- Life expectancy of greater than 12 weeks.
- ECOG performance status < or equal to 2.
- Patients must have normal organ and marrow function as defined below:
- Absolute neutrophil count: > or equal to 1,500/mcL,
- Hemoglobin: > or equal to 9 mg/dL,
- Platelets: > or equal to 100,000/mcL,
- Total bilirubin: < or equal to 1.5 X institutional upper limit of normal,
- AST(SGOT)/ALT(SGPT): < or equal to 2.5 X institutional upper limit of normal
without liver metastases, OR < or equal to 5 X institutional upper limit of
normal if documented liver metastases,
- Creatinine: < or equal to 2.0 mg/dL, OR calculated creatinine clearance greater
than or equal to 50 mL/min (calculated by the Cockcroft and Gault method).
- Ability to understand and the willingness to sign a written informed consent
- Both men and women are eligible.
- Use of an effective means of contraception in subjects of child-bearing potential.
- Negative serum or urine beta-HCG pregnancy test at screening for patients with
- Patients may not be receiving any other investigational agents.
- Prior use of Abraxane for metastatic disease or in the adjuvant setting.
- Metastatic lesions identifiable only by PET.
- Patients may not be receiving concurrent chemotherapy for treatment of metastatic
- Active brain metastases: evidence of progression < or equal to 3 months after local
therapy (patients should be asymptomatic and off corticosteroids and anticonvulsants
for at least 3 months prior to study entry).
- Patients with brain metastases must have at least one site of measurable disease
outside of the central nervous system.
- Uncontrolled concurrent illness including, but not limited to, ongoing or active
infection, history of recent myocardial infarction, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements.
- Pregnant or lactating women are excluded. Because there is an unknown but potential
risk for adverse events in nursing infants secondary to treatment of the mother,
breastfeeding should be discontinued if the mother is treated. These potential risks
may also apply to other agents used in this study.
- A prior invasive malignant disease within five years except for skin cancer (squamous
cell or basal cell carcinoma).
- Patients with known history of HIV or Hepatitis B because of potential for added
toxicity from treatment regimen.
- Dementia or altered mental status that would prohibit the understanding of informed